QT Imaging Holdings, Inc. (OTCQB: QTIH), a medical device company focused on advancing breast health through radiation-free imaging technology, has announced the appointment of Satrajit Misra as its new Chief Commercial Officer (CCO). The appointment marks a strategic milestone as the company transitions toward a software-as-a-service (SaaS) and biomarker-driven business model. Dr. Raluca Dinu, CEO of QT Imaging, welcomed Misra, highlighting his extensive experience in scaling medical imaging enterprises and building strong relationships with leading radiology and oncology experts. She emphasized that Misra’s leadership will be key to accelerating the commercial adoption of QT Imaging’s innovative diagnostic platforms. Misra brings over 30 years of progressive leadership in radiology, oncology, and molecular imaging. Most recently, he served as Executive Senior Vice President and Chief Sales and Marketing Officer at Canon Medical Systems USA, a strategic partner of QT Imaging. Prior to that, he held senior roles at Philips and Siemens Healthcare, where he led business development, marketing, and integration initiatives across global markets. He holds a Bachelor of Science and a Bachelor of Technology in applied physics from the University of Calcutta, studied at the University of Leeds, and earned a certificate in negotiation from Harvard Business School. In his new role, Misra will lead commercial expansion, drive clinical partnerships, and position QT Imaging’s Breast Acoustic CT™ technology as a preferred solution for supplemental breast screening and precision diagnostics. The technology uses low-frequency sound waves to create detailed breast images without radiation, contrast agents, or compression—offering a safer, more comfortable alternative for patients. “I’m excited to join QT Imaging at such a transformative moment,” said Misra. “Having worked closely with Raluca and her team through our partnership with Canon USA, I’ve seen firsthand the speed and impact of QTI’s progress in redefining breast health management. I look forward to helping scale the technology, expand the product pipeline, and deliver greater value to patients and shareholders.” QT Imaging is committed to making medical imaging safer, more accessible, and patient-centered. The company’s mission is to improve global health outcomes by advancing early disease detection through innovative, non-invasive imaging solutions. The company’s forward-looking statements, including those related to product development, commercialization, and revenue growth, are subject to risks and uncertainties, including clinical results, market demand, supply chain issues, regulatory approvals, and the ability to attract and retain talent. For a full list of risk factors, investors should refer to QT Imaging’s SEC filings. For more information, visit www.qtimaging.com.